Target intelligence / Profile preview

Snake venom secretory phospholipase A2 (svPLA2)

Target
svPLA2
Molecular classification
Enzyme, Secreted phospholipase A2
01

Overview

Snake venom secretory phospholipase A2 (svPLA2) enzymes are critical, highly toxic components found in the venoms of almost all medically important snake families, including Viperidae and Elapidae. These small, calcium-dependent enzymes catalyze the hydrolysis of the sn-2 ester bond of membrane glycerophospholipids, releasing free fatty acids (such as arachidonic acid) and lysophospholipids. This enzymatic activity, along with non-enzymatic interactions, leads to severe pathological effects including myonecrosis, neurotoxicity, paralysis, acute kidney injury, and systemic inflammatory responses. Consequently, svPLA2 is a primary therapeutic target for treating snakebite envenomation, which is classified as a high-priority neglected tropical disease. Small-molecule inhibitors, most notably varespladib and its orally bioavailable prodrug varespladib-methyl, act as potent competitive inhibitors of svPLA2, effectively neutralizing its toxicity and offering a promising adjunct or alternative to traditional antibody-based antivenoms.

Other names
Phospholipase A2 venom toxinsSnake venom phospholipase A2Viper venom phospholipase A2vvPLA2Venom secretory phospholipase A2svPLA2sVenom PLA2
02

Mechanism of action

Inhibition of snake venom secretory phospholipase A2 (svPLA2) enzymatic activity, preventing the hydrolysis of cell membrane phospholipids and subsequent release of inflammatory fatty acids and lysophospholipids, thereby mitigating tissue damage, neurotoxicity, and systemic inflammation.

03

Biological functions

Lipid metabolismPhospholipid hydrolysisCell deathApoptosisNecrosisInflammationOxidative stress
04

Disease associations

Snakebite envenomingMyotoxicityNeurotoxicityInflammationAcute kidney injuryAcute liver injuryHemotoxicity
05

Safety considerations

Off-target inhibition of human mammalian secretory phospholipases A2 (sPLA2s) which are involved in normal physiological processesPotential for systemic side effects or immunosuppressionIncomplete neutralization of other venom components (e.g., metalloproteinases, serine proteases) requiring combination therapyRisk of hypersensitivity or allergic reactions to therapeutic agents
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Snakebite Severity Score (SSS)Serum creatinine (SCr)Blood urea nitrogen (BUN)Neutrophil gelatinase-associated lipocalin (NGAL)Kidney injury molecule-1 (KIM-1)Interleukin-6 (IL-6)Tumor necrosis factor-alpha (TNF-alpha)

Beyond the preview

Go deeper on Snake venom secretory phospholipase A2 (svPLA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Snake venom secretory phospholipase A2 (svPLA2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call